Khalid Kal Mentak Ph D Catalyst Technology Innovation

  • Slides: 12
Download presentation
Khalid “Kal” Mentak, Ph. D Catalyst Technology Innovation Group Palo Alto, CA Empowering IP

Khalid “Kal” Mentak, Ph. D Catalyst Technology Innovation Group Palo Alto, CA Empowering IP from Idea to Market The Glakolens Case

Historical Perspective § Companies in the Biotech and Healthcare segment use Universities as fundamental

Historical Perspective § Companies in the Biotech and Healthcare segment use Universities as fundamental research centers through sponsored research programs § IP is assigned to sponsors through licensing agreements § In most cases IP is not managed properly based on the lack of incentives for value creation

The landscape has changed § Universities are taking a proactive approach to monetize IP

The landscape has changed § Universities are taking a proactive approach to monetize IP independently of sponsors § Incubators, accelerators, and investment centers are playing an increasing role in leveraging academic IP § Better IP quality and management through outside due diligence and independent investors

The New Value Creation Model § Bring investment, regulatory, and entrepreneurial expertise to universities

The New Value Creation Model § Bring investment, regulatory, and entrepreneurial expertise to universities § Educate students and faculty members on how to integrate value creation into creating innovative IP § Highlight the role of strong and well managed IP in improving lives and driving innovation

§ Bringing VCs, faculty members, and entrepreneurs together to drive healthcare innovation § Educational

§ Bringing VCs, faculty members, and entrepreneurs together to drive healthcare innovation § Educational curriculum with intensive interactions with the VC community in Silicon Valley § A strong focus on creating and managing IP within the academic environment

Value-Driven IP creation Model Capital Clinical Need Project Generation Business Advisory Group IP Creation

Value-Driven IP creation Model Capital Clinical Need Project Generation Business Advisory Group IP Creation Strategy Management • Execution Plan • Milestones & Goals • First-in-Man Regulatory Advisory Group • Clinical Need Assessment • MKT Opportunity Assessment • Project Scope Analysis

The Glakolens Case Unmet Clinical Need § Glaucoma is a chronic disease with no

The Glakolens Case Unmet Clinical Need § Glaucoma is a chronic disease with no cure § 70 M people worldwide have glaucoma - € 5 B Market § The 2 nd leading cause of blindness globally § It develops due to increased intraocular pressure (IOP) § The ability to monitor IOP over an extended period of time is critical to delivering efficient therapy § No viable product on the market

The Glakolens Case The Solution Development and market introduction of the first noninvasive wireless,

The Glakolens Case The Solution Development and market introduction of the first noninvasive wireless, contact lensbased IOP monitoring system capable of collecting data over prolonged periods of time

The Glakolens Case The Technology § Based on a low cost and easy to

The Glakolens Case The Technology § Based on a low cost and easy to manufacture passive biosensor. § Accurately monitors fluctuations in IOP by measuring changes in the geometry of a sensor placed on the cornea. § First non-invasive, wireless, and continuous IOP monitoring system

The Glakolens Case Investment-driven IP Assessment § § § § Value-driven evaluation Deep understanding

The Glakolens Case Investment-driven IP Assessment § § § § Value-driven evaluation Deep understanding of the glaucoma market KOL assessment Market acceptance Regulatory path Sales strategy Exit strategy

The Glakolens Case Conventional IP Assessment § § Patentability FTO Infringement Patent coverage based

The Glakolens Case Conventional IP Assessment § § Patentability FTO Infringement Patent coverage based on business strategy

Leveraging IP to Get from Idea to Market Timeframe Milestone Year 1 Produce Prototype

Leveraging IP to Get from Idea to Market Timeframe Milestone Year 1 Produce Prototype File for International Patent Year 2 Produce Functional Model Obtain Issued Patents Initiate Validation Perform Full Validation Expand IP Year 3 Strategic positioning for potential exit or licensing deal Pitch the product to various strategics in ophthalmology, optometry, and telemedicine Year 4 Obtain CE Mark Perform Clinical Validation Launch in Selected Markets